We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam (ALNY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
Analysts on Wall Street project that Alnylam Pharmaceuticals (ALNY - Free Report) will announce quarterly earnings of $2.19 per share in its forthcoming report, representing a decline of 24.5% year over year. Revenues are projected to reach $1.45 billion, increasing 16% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 7.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Alnylam metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Revenues- Product revenues, net' will reach $1.30 billion. The estimate indicates a change of +52.9% from the prior-year quarter.
Analysts expect 'Revenues- Royalty revenue' to come in at $82.08 million. The estimate suggests a change of +77.7% year over year.
The consensus estimate for 'Net Product Revenue- Oxlumo' stands at $55.69 million. The estimate indicates a year-over-year change of +5.4%.
According to the collective judgment of analysts, 'Net Product Revenue- Givlaari' should come in at $87.10 million. The estimate suggests a change of +17.9% year over year.
Analysts' assessment points toward 'Net Product Revenue- Onpattro' reaching $22.27 million. The estimate indicates a year-over-year change of -43%.
Analysts predict that the 'Net Product Revenue- Amvuttra' will reach $1.15 billion. The estimate indicates a change of +68.1% from the prior-year quarter.
Shares of Alnylam have demonstrated returns of -10.7% over the past month compared to the Zacks S&P 500 composite's -0.2% change. With a Zacks Rank #4 (Sell), ALNY is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Alnylam (ALNY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Analysts on Wall Street project that Alnylam Pharmaceuticals (ALNY - Free Report) will announce quarterly earnings of $2.19 per share in its forthcoming report, representing a decline of 24.5% year over year. Revenues are projected to reach $1.45 billion, increasing 16% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 7.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Alnylam metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Revenues- Product revenues, net' will reach $1.30 billion. The estimate indicates a change of +52.9% from the prior-year quarter.
Analysts expect 'Revenues- Royalty revenue' to come in at $82.08 million. The estimate suggests a change of +77.7% year over year.
The consensus estimate for 'Net Product Revenue- Oxlumo' stands at $55.69 million. The estimate indicates a year-over-year change of +5.4%.
According to the collective judgment of analysts, 'Net Product Revenue- Givlaari' should come in at $87.10 million. The estimate suggests a change of +17.9% year over year.
Analysts' assessment points toward 'Net Product Revenue- Onpattro' reaching $22.27 million. The estimate indicates a year-over-year change of -43%.
Analysts predict that the 'Net Product Revenue- Amvuttra' will reach $1.15 billion. The estimate indicates a change of +68.1% from the prior-year quarter.
View all Key Company Metrics for Alnylam here>>>Shares of Alnylam have demonstrated returns of -10.7% over the past month compared to the Zacks S&P 500 composite's -0.2% change. With a Zacks Rank #4 (Sell), ALNY is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .